AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Avalo Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $621.57M | $197.05M |
| Enterprise Value | $149.37M | $106.56M |
| PB Ratio | 1.39 | 2.14 |
| P/TBV Ratio | 1.42 | 2.46 |
Income (trailing twelve months)
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$91.36M | -$21.44M |
| Pretax Income | -$100.16M | -$14.45M |
| Net Income | -$100.33M | -$22.46M |
| EBITDA | -$91.25M | -$16.91M |
| EPS (Diluted) | -$4.75 | -$0.83 |
Returns
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.3% | -53.1% |
| Return on Assets (ROA) | -32.5% | -41.0% |
| Return on Capital Employed (ROCE) | -19.5% | -37.8% |
Growth
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -85.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -61.2% | 6.42% |
Balance sheet
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $472.20M | $62.42M |
| Net Cash (Debt) | $472.20M | $15.68M |
| Net Cash Per Share | $8.80 | $0.65 |
| Equity (Book Value) | $448.66M | $48.79M |
| Book Value Per Share | $8.37 | $1.36 |
| Tangible Book Value | $438.16M | $23.06M |
| Working Capital | $386.80M | $75.77M |
Financial position
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 19.31 | 3.30 |
| Quick Ratio | 22.35 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$68.29M | -$12.35M |
Efficiency
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$4.36M | -$732.08K |
| Employee Count | 23 | 73 |
Dividends and yields
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -16.1% | -21.2% |
Shares
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 53,630,000 | 59,128,900 |
| Shares Change (YoY) | 125.8% | 11.1% |
| Shares Change (QoQ) | 114.7% | 0.54% |
| Float | 53,248,900 | 48,744,500 |
| Shares Held by Insiders | 0.71% | 11.8% |
| Shares Held by Institutions | 135.4% | 59.4% |
Taxes
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Income Tax | $171.00K | $91.50K |
Scores
| Measure | Avalo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 7.75 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Avalo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.